Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | NNMT | P40261 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLQ | O75417 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | SPR | P35270 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 3/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29425147 | 1.00 | GAA (0.42) | GAANNMTMAPTKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL31418668 | 0.98 | GAA (0.41) | GAANNMTMAPTKDM4EALDH1A1 | |
| SCHEMBL4750181 | 0.86 | GAA (0.42) | GAAMAPTKDM4EALDH1A1ABL1 | |
| SCHEMBL474122 | 0.84 | KDM4E (0.44) | GAANNMTMAPTKDM4EALDH1A1 | |
| SCHEMBL29551416 | 0.84 | KDM4E (0.44) | GAANNMTMAPTKDM4EALDH1A1 | |
| SCHEMBL24769148 | 0.83 | POLQ (0.42) | GAAMAPTPOLQNQO2 | |
| SCHEMBL30017365 | 0.83 | POLQ (0.42) | GAAMAPTPOLQNQO2 | |
| SCHEMBL26115003 | 0.83 | KDM4E (0.45) | GAANNMTMAPTKDM4EALDH1A1 | |
| SCHEMBL3652621 | 0.83 | BAZ2B (0.51) | GAAMAPTKDM4EALDH1A1GLA | |
| SCHEMBL8495483 | 0.82 | GAA (0.42) | GAANNMTMAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4705298-A2 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | Moma Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12559508-B2 | Semi-saturated bicyclic derivatives and related uses | MOMA THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260049074-A1 | THIADIAZOLYL DERIVATIVES | IDEAYA BIOSCIENCES, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4695241-A1 | THIADIAZOLONE DERIVATIVES, COMPOSITIONS AND USES THEREOF | Danatlas Pharmaceuticals Co., Ltd. (CN) | 2026-02-18 | — | — | EP | disclosed |
| EP-4688772-A1 | BIARYL DERIVATIVES AND RELATED USES | Moma Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260034113-A1 | THIADIAZOLONE DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
| US-20260015360-A1 | BIARYL DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2026-01-15 | — | — | US | disclosed |
| US-12509454-B2 | Thiadiazolyl derivatives | IDEAYA BIOSCIENCES, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250346590-A1 | THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED (GB) | 2025-11-13 | — | — | US | disclosed |
| US-20130237555-A1 | Aryl Ether-Base Kinase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237555-A1 | Aryl Ether-Base Kinase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237555-A1 | Aryl Ether-Base Kinase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-09-12 | — | — | US | disclosed |
| WO-2013134036-A1 | ARYL ETHER-BASE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-09-12 | — | — | WO | disclosed |
| US-20130150372-A1 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-8420647-B2 | 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-04-16 | — | — | US | disclosed |
| EP-1986645-B1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC (US) | 2012-01-04 | — | — | EP | disclosed |
| WO-2011089099-A1 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-28 | — | — | WO | disclosed |
| US-20110178089-A1 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2011-07-21 | — | — | US | disclosed |
| WO-2007089512-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049074-A1 | THIADIAZOLYL DERIVATIVES | POLH, POLM, POLD1 | GAA 2465/4885NNMT 3568/4885MAPT 4800/4885 |
| US-20260015360-A1 | BIARYL DERIVATIVES AND RELATED USES | POLB, POLA1, POLN | GAA 382/4885NNMT 2581/4885MAPT 2064/4885 |
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | POLA1, SUB1, CTDSP1 | GAA 477/4885NNMT 2435/4885MAPT 2143/4885 |
| US-12559508-B2 | Semi-saturated bicyclic derivatives and related uses | POLA1, CTDSP1, SUB1 | GAA 909/4885NNMT 3347/4885MAPT 2256/4885 |
| US-20130150372-A1 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS | P2RY1, GPBAR1, ADORA1 | GAA 1442/4885NNMT 159/4885MAPT 3655/4885 |
| US-20250346590-A1 | THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS AND USES THEREOF | POLQ, POLK, POLB | GAA 881/4885NNMT 1286/4885MAPT 3664/4885 |
| US-20260034113-A1 | THIADIAZOLONE DERIVATIVES, COMPOSITIONS AND USES THEREOF | SRD5A2, NR3C2, SRD5A1 | GAA 4391/4885NNMT 1303/4885MAPT 2257/4885 |
| US-20130237555-A1 | Aryl Ether-Base Kinase Inhibitors | AAK1, NCK1, ADCK1 | GAA 3155/4885NNMT 2636/4885MAPT 2717/4885 |
| US-20110178089-A1 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS | P2RY1, GPBAR1, ADORA1 | GAA 1442/4885NNMT 159/4885MAPT 3655/4885 |
| US-12509454-B2 | Thiadiazolyl derivatives | POLD1, POLQ, DNA2 | GAA 2449/4885NNMT 3724/4885MAPT 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.